the efficacy of single dose rasburicase in prevention or treatment of tumor lysis syndrome in children

نویسندگان

samin alavi pediatric congenital hematologic disorders research center, shahid beheshti university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (shahid beheshti university of medical sciences)

maryam ebadi department of pediatrics, division of hematology and oncology, university of minnesota

sadaf esteghamati pediatric congenital hematologic disorders research center, shahid beheshti university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی شهید بهشتی (shahid beheshti university of medical sciences)

mohammad kaji yazdi department of pediatric hematology and oncology. tehran university of medical sciences, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (tehran university of medical sciences)

چکیده

background: tumor lysis syndrome (tls) is a major metabolic complication in patients with malignancy after initiation of chemotherapy or spontaneously without treatment. the role of rasburicase (a recombinant urate-oxidase enzyme) in prevention and treatment of tls has been demonstrated in recent years. we aimed to investigate the efficacy of a single dose of rasburicase in reducing the risk of tls in children at high risk.  methods: we conducted a retrospective analysis of 560 children with various malignancies in a single referral center. on the basis of the reference values previously established in our center hyperuricemia and tls were defined. tumor lysis syndrome development was the primary outcome. 48 children with a mean age of 7.1 years (range: 3 months to 15.8 years) developed tumor lysis syndrome. the most common malignancies were b-precursor acute lymphoblastic leukemia (all) (45%) followed by non-hodgkin lymphoma (nhl) and wilms' tumor (each 10.4%), respectively. they received normal saline intravenously at a rate of 4-5 l/m2/day in 24-48 hours prior to initiating chemotherapy. plasma samples were drawn to detect uric acid, calcium, phosphate, potassium, creatinine and blood urea nitrogen (bun) 4 hours before administering a single dose of iv rasburicase (0.2 mg/kg over 30 minute). laboratory markers were evaluated again 4 and 24 hours after administering rasburicase. results: all patients with diagnosis of tls had significantly decreased uric acid levels following single dose of rasburicase except 1 patient (2.1%) (p< 0.001). mean plasma uric acid concentration before treatment was 10.0±4.2 mg/dl and 4 hours after treatment declined to 2.2±5.5 (p< 0.001). hyperphosphatemia was also detected in 43.7% of these 48 cases which significantly decreased to 16.7% (p=0.012). plasma uric acid levels remained low one day after treatment. no side effects were detected.  conclusion: rasburicase is a safe and highly effective drug in children with hyperuricemia in the setting of malignancy at risk of developing tls.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The Efficacy of Single Dose Rasburicase in Prevention or Treatment of Tumor Lysis Syndrome in Children

Background: Tumor lysis syndrome (TLS) is a major metabolic complication in patients with malignancy after initiation of chemotherapy or spontaneously without treatment. The role of Rasburicase (a recombinant urate-oxidase enzyme) in prevention and treatment of TLS has been demonstrated in recent years. We aimed to investigate the efficacy of a single dose of rasburicase in reducing the risk of...

متن کامل

Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase

Tumor lysis syndrome (TLS) is a potentially life-threatening condition that occurs in oncologic and hematologic patients with large tumor burden, either due to cytotoxic therapy or, less commonly, spontaneously because of massive tumor cell lysis. TLS is clinically characterized by acute renal failure, hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. While limited options are a...

متن کامل

Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.

Rasburicase is currently approved at a dosage of 0.15-0.2 mg/kg once/day for 5 days in pediatric patients with cancer to lower plasma uric acid concentrations and manage tumor lysis syndrome (TLS). Information on rasburicase dosing in adults is limited, with some data on using rasburicase as a single dose instead of multiple daily doses. Therefore, we evaluated the efficacy of a single dose of ...

متن کامل

Rasburicase for prevention of hyperuricemia and tumor lysis syndrome.

• Hyperuricemia associated with tumor lysis syndrome is a potentially serious complication most frequently seen during chemotherapy for malignancies with large tumor burden and highly proliferative cells, such as aggressive lymphomas and leukemia.1-3 Hyperuricemia usually occurs in association with other metabolic abnormalities, including hyperphosphatemia, hyperkalemia, hypocalcemia, and azote...

متن کامل

The Prevalence of Tumor Lysis Syndrome in Children and Adolescents with Cancer in Hamedan Province, Iran

Background: Tumor lysis syndrome caused by widespread tumor cell damage may lead to electrolyte imbalances and express as metabolic disturbance causing clinical abnormalities. Patients and Methods: All patients younger than 16 years with documented malignancy candidate for chemotherapy, in Hamedan province of Iran were enrolled. Results: Out of 69 cancer patients the laboratory form of tumor ...

متن کامل

the effect of the record infancy in crimilly acts of guilties (in karaj city)

چکیده یکی از مهمترین دغدغه های بزرگ جوامع بشری، از دیر باز تا کنون که ذهن پژوهشگران و متخصصان بهداشت روانی و اجتماعی و دولتها رابه خود مشغول داشته، مسأله ی بزهکاری می باشد. شناخت کامل پدیده ی بزهکاری و بزهکار، علل وعوامل سقوط یک انسان، چگونگی درمان وی و درنهایت پیشگیری ازبزهکاری ودریک کلام سالم سازی یک جامعه، رسالت عظیم، انسانی ومقدسی می باشد که با بررسی شخصیت مجرم یعنی[ انسانی که تحت شرای...

15 صفحه اول

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
iranian journal of blood and cancer

جلد ۸، شماره ۲، صفحات ۳۳-۳۷

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023